Literature DB >> 2249899

Type-II estrogen binding sites in a lymphoblastoid cell line and growth-inhibitory effect of estrogen, anti-estrogen and bioflavonoids.

G Scambia1, F O Ranelletti, P Benedetti Panici, M Piantelli, C Rumi, F Battaglia, L M Larocca, A Capelli, S Mancuso.   

Abstract

Type-II estrogen-binding sites (type-II EBS) have been demonstrated in the human lymphoblastoid cell line IM-9 using a whole-cell assay with (6,7-3H) estradiol (3H-E2) as tracer. Competition analysis showed that the anti-estrogen tamoxifen and the flavonoids quercetin and rutin competed for (3H)-E2 binding to type-II EBS. Growth experiments demonstrated that diethylstilbestrol (DES) tamoxifen (TAM), quercetin and rutin exerted a reversible dose-dependent inhibition of cell proliferation in the range of concentrations between 10 nM and 10 microM. The relative binding affinity of quercetin, rutin, DES and TAM for type-II EBS correlated well with their potency as cell growth inhibitors. Moreover, hesperidin, a flavonoid which does not bind to type-II EBS, was ineffective in inhibiting cell growth. Cell-cycle analysis showed that the growth-inhibitory effect of DES, TAM or quercetin was due to a blocking effect in the G0-G1 phases. Our results suggest that high estrogen and anti-estrogen concentrations and flavonoids may regulate IM-9 cell growth through a common mechanism involving a binding interaction with type-II EBS.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2249899     DOI: 10.1002/ijc.2910460627

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  8 in total

1.  Luteolin and gefitinib regulation of EGF signaling pathway and cell cycle pathway genes in PC-3 human prostate cancer cells.

Authors:  Barry M Markaverich; Mary Vijjeswarapu; Kevin Shoulars; Mary Rodriguez
Journal:  J Steroid Biochem Mol Biol       Date:  2010-06-15       Impact factor: 4.292

2.  Regulation of cell cycle and RNA transcription genes identified by microarray analysis of PC-3 human prostate cancer cells treated with luteolin.

Authors:  Kevin Shoulars; Mary Ann Rodriguez; Trellis Thompson; Barry M Markaverich
Journal:  J Steroid Biochem Mol Biol       Date:  2009-10-27       Impact factor: 4.292

3.  Quercetin potentiates the effect of adriamycin in a multidrug-resistant MCF-7 human breast-cancer cell line: P-glycoprotein as a possible target.

Authors:  G Scambia; F O Ranelletti; P B Panici; R De Vincenzo; G Bonanno; G Ferrandina; M Piantelli; S Bussa; C Rumi; M Cianfriglia
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

4.  Quercetin inhibits the growth of a multidrug-resistant estrogen-receptor-negative MCF-7 human breast-cancer cell line expressing type II estrogen-binding sites.

Authors:  G Scambia; F O Ranelletti; P Benedetti Panici; M Piantelli; G Bonanno; R De Vincenzo; G Ferrandina; L Pierelli; A Capelli; S Mancuso
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

5.  A low-affinity estrogen-binding site in pregnant rat uteri: analysis and partial purification.

Authors:  W G Gray; E E Biswas; N Bashirelahi; S B Biswas
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-22       Impact factor: 11.205

6.  Luteolin Regulation of Estrogen Signaling and Cell Cycle Pathway Genes in MCF-7 Human Breast Cancer Cells.

Authors:  Barry M Markaverich; Kevin Shoulars; Mary Ann Rodriguez
Journal:  Int J Biomed Sci       Date:  2011

7.  Multiple Sites of Type II Site Ligand (Luteolin and BMHPC) Regulation of Gene Expression in PC-3 Cells.

Authors:  Barry M Markaverich; Mary Vijjeswarapu
Journal:  Int J Biomed Sci       Date:  2012-12

8.  Effects of coumestrol on estrogen receptor function and uterine growth in ovariectomized rats.

Authors:  B M Markaverich; B Webb; C L Densmore; R R Gregory
Journal:  Environ Health Perspect       Date:  1995-06       Impact factor: 9.031

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.